News

Freeline’s technology uses engineered adeno-associated virus (AAV) vectors for the treatment of bleeding and other debilitating disorders. Freeline will deploy their proprietary manufacturing platform for production of clinical

Argentum Pharmaceuticals brought the challenge to the patent, in a proceeding called inter partes review. Argentum disputed all claims of Janssen's U.S. Patent No. 8,822,438, which will expire on

The new agreement focuses on the synthesis and delivery of custom libraries to AstraZeneca as well as the transfer of the DEX platform, allowing for in-house screening of

The round was co-led by new investor Horizons Ventures of Hong Kong and existing investor The Column Group, and joined by private investors including Jerome Dahan. Patrick Zhang

Kymriah will be assessed under a priority review by the US Food and Drug Administration (FDA) for the treatment of adult patients with DLBCL who are ineligible for

Sandoz biopharmaceuticals development global head Mark Levick said: "When patients are dealing with a chronic disease, it is imperative they have access to important medication that will help

Adynovi is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding. It

Both OS and PFS were defined to be the dual primary endpoints of the pivotal late-stage trial dubbed KEYNOTE-189. The trial assessed the combination of Keytruda, Lilly’s pemetrexed

DIPG disease is mostly observed in young children with a median survival of nine months. Midatech Pharma said the approval of MTX110 trial is a big step towards development